Merck & Co's second-quarter profits drop by 12% - update
This article was originally published in Scrip
Executive Summary
Merck & Co's second-quarter net income fell by 12%, hit by negative currency effects and poor sales of its cholesterol drugs Zetia (ezetimibe) and Vytorin (ezetimibe plus simvastatin).